You are here: Industry Insights > Novo Nordisk

News List

Novo Nordisk wins FDA green light for 'holy grail' diabetes drug Rybelsus fiercepharma
September 26, 2019
Novo has not shared Rybelsus' list price, but the drug "will be competitively priced within the GLP-1 category," a company spokesman said by email.
Novo's Rybelsus, check. Here are the major launches coming up next fiercepharma
September 26, 2019
The drug drew the interest of Bristol-Myers Squibb, which is set to swallow Celgene in a megamerger. Luspatercept represents a "high value near-term asset," BMS has said.
Novo's Ozempic launch kicks into gear ahead of oral semaglutide FDA decision fiercepharma
August 11, 2019
Novo Nordisk has suffered some well-documented insulin woes, but now the company has not just two, but three GLP-1 drugs stepping up to drive growth. And if all goes well at the FDA, another big approval is on tap this year.
Novo Nordisk buys out Purdue pill plant to gear up for oral semaglutide fiercepharma
August 07, 2019
With its next-gen oral GLP-1 semaglutide up for an FDA approval, Novo Nordisk is hunting for opportunities to boost its supply chain. Now, with Purdue Pharma on the ropes, it has found one in North Carolina.
Novo Nordisk’s Recombinant Coagulation Factor Ⅷ Applied for Marketing Ahead of Chiatai Tianqing! PharmaSources/Caicai
July 23, 2019
The Blue Ocean Market of Hemophilia Drugs Exceeding RMB10 Billion
FDA approves Novo Nordisk’s type 2 diabetes drug Victoza pharmaceutical-technology
June 20, 2019
Novo Nordisk has secured approval for Victoza (liraglutide) from the US Food and Drug Administration (FDA) to treat paediatric patients aged ten years or older with type 2 diabetes.
Greater Manchester joins Cities Changing Diabetes initiative pharmatimes
June 18, 2019
Novo Nordisk has named Greater Manchester as the 22nd city, and second in the UK, to join Cities Changing Diabetes, a scheme designed to address the dramatic rise of type II diabetes in urban areas.
Novo Nordisk’s Victoza found to cut blood sugar in children pharmatimes
April 29, 2019
The results showed that the safety profile of Victoza seen in children and adolescents was similar to that seen in adults.
Novo Nordisk files for EU approval of Ozempic in type II diabetes pharmatimes
April 28, 2019
Novo Nordisk has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Ozempic (oral semaglutide), for the treatment of type II diabetes.
Gilead announces Novo Nordisk NASH partnership after new data revealed pharmatimes
April 16, 2019
Gilead Sciences has announced its intent to initiate a clinical collaboration with Novo Nordisk for a trial ……

Previous page 1 2 3 4 5 6 7 8 9 10 ... 13 14 Next page